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Abstract
This study investigates angiogenesis and the expression of thrombospondin 1 in invasive ductal carcinoma of the breast and
their possible relation to platelet counts and platelet activity. The study included 20 cases of invasive ductal carcinoma.
Platelet activity was evaluated by determining thromboxane B2 and cyclic guanosine monophosphate (cGMP) levels by
enzyme immunoassay (EIA). Thrombospondin (TSP) 1 and CD34 expression was studied immunohistochemically. Mean
platelet count of the patient group was significantly greater than the mean platelet count of the control group (PB0.05).
The platelet counts were positively correlated with tumour size (r 0.609; PB0.01). Platelet counts were higher in the
patients who had grade 3 microvessel density (PB0.05). The mean basal platelet cGMP level in the patient group was
significantly lower than it was in the control group (PB0.05). Focal TSP immunoreactivity was detectable in 5 (20%) cases
in the tumour cells, and in 9 (45%) cases in the stroma. We did not find any correlation between TSP-1 staining and
angiogenesis, platelet counts, platelet activity, and the histological prognostic parameters. Our study confirms the essential
role of platelets in tumour growth and angiogenesis. Decreased levels of cyclic guanosine monophosphate (cGMP) in the
patient group may cause platelet hyperreactivity. Although thrombospondin 1 may be upregulated in malignant breast
tissue, this is not sufficient for tumour growth and dissemination according to our results.
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Introduction
Breast cancer is the most common carcinoma in
women. Invasive ductal carcinoma not otherwise
specified forms the largest group of invasive breast
cancers (1). It comprises between 40% and 75% in
published series (2).
Breast cancer is a heterogeneous disease char-
acterized by variable growth rates and metastatic
potentials. Prognostic parameters which can be used
to predict the behaviour of the tumours are sought.
There are reports that observed that angiogenesis is
an independent and significant prognostic marker
for survival in early-stage breast carcinoma; several
reports, however, have not been able to confirm the
value of it (3).
Thrombospondin (TSP) is a matricellular pro-
tein that functions as an angiogenesis inhibitor (4).
Studies of invasive tumours have demonstrated
TSP-1 in the tumour stroma and have reported
an inverse correlation between the presence of TSP-
1 and tumour angiogenesis (5 8). To determine the
role of TSP-1 in breast cancer and breast cancer
angiogenesis, Byrne et al. have measured TSP-1 in
plasma and tumour cytosols and compared levels to
established clinicopathological prognostic para-
meters and intratumoural microvessel density.
They concluded that circulating levels of TSP-1
appear to be a marker of breast cancer aggressive-
ness and in breast cancer may have a proangiogenic
rather than antiangiogenic role (9).
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is the major protein of platelet a granules and is
expressed on the cell surface upon platelet activation
(10). Experimental and clinical data indicate that
tumour cell platelet interactions are important for
tumour progression and metastasis (11).
In the present study, we evaluated angiogenesis
and the expression of TSP-1 immunohistochemi-
cally in invasive ductal carcinoma of the breast and
their possible relation to platelet counts and platelet
activity in breast carcinoma patients. We have also
analysed the effects of angiogenesis, TSP-1 expres-
sion, platelet counts, and platelet activation on
prognostic histological parameters.
Materials and methods
We performed a prospective clinical and laboratory
study. Procedures followed were approved by the
Ankara University Human Ethics Committee, and
they were in accordance with the Helsinki Declara-
tion of 1975, revised 1983.
The study group comprised 20 patients with
primary operable invasive ductal carcinoma of the
breast. All of the patients underwent modified
radical mastectomy. The age range was 37 88 years,
with a mean age of 56. They were non-smokers and
were not prescribed acetylsalicylic acid in the two
weeks prior to the operation.
The control group for blood sample analysis
included 14 healthy women with an age range of
34 76 years, with a mean age of 50 years. They were
non-smokers and were not prescribed acetylsalicylic
acid in the two weeks prior to sampling. From their
histories of disease, it was evident that none had ever
suffered from cancer or other chronic diseases.
Blood sample analysis
Blood samples of patients were collected prior to the
operation. Platelet-rich plasma (PRP) was obtained
by centrifugation of citrated blood at 300 rpm for
15 min. Platelets were separated by centrifugation
at 1200 rpm for 15 min and were washed twice
before being resuspended in a HEPES-buffered
Tyrode solution containing 138 mM NaCl,
0.36 mM NaH2PO4, 2.9 mM KCl, 1 mM MgCl2,
5 mM glucose, and 20 mM N-2-Hydroxyethylpiper-
azine-N?-2-Ethanesulphonic Acid (HEPES) (pH
7.4). The platelet count was adjusted to 300 10
9/L.
Platelet activation was evaluated by determining
thromboxane B2 (TxB2), the stable metabolite of
thromboxane A2 (TxA2), and cyclic guanosine
monophosphate (cGMP) levels. Thrombin (Chron-
olog Corp., PA, USA) in 0 8 U/ mL final concentra-
tion was added to the platelet suspension and was
incubated for 15 min. The supernatant was prepared
by centrifugation of thrombin-induced platelet sus-
pensionfor3 minat10,000 rpm.TxB2wasevaluated
by enzyme immunoassay (EIA) in the supernatants.
The results were expressed as ng/mL (12,13).
For the determination of platelet cGMP con-
tent, PRP was incubated with sodium nitroprusside
(SNP), a source of nitric oxide (NO), for 15 min,
and ice-cold trisodium citrate was added. Platelets
were pelleted by centrifugation, and 0.3 mL 96%
ethanol was added. After evaporation of ethanol,
0.3 mL tris-ethylenediaminetetraacetic acid (EDTA)
buffer was added. After 10 min, 0.1 mL of super-
natant was tested by EIA (14). EIA kits were obtained
from Cayman Chemical (MI, USA).
Histopathological analysis
Surgical resected specimens from 20 patients with
operable breast carcinoma were used. Tumour size
wasreportedasthelargestdiameter.Tumoursizewas
graded as: 1 (52 cm), or 2 ( 2 cm). Tumour
samples were fixed in 10% neutral buffered formalin,
embedded in paraffin, cut into sections of 3 mm
thickness, and stained with haematoxylin-eosin. His-
tological diagnosis was invasive ductal carcinoma in
all cases. Tumour grading, nodal status, and vascular
invasion assessment were performed on haematox-
ylin-eosin-stained sections. Tumour grade was deter-
mined according to the criteria of the modified
version of Bloom and Richardson’s method (15).
Statusofaxillarylymphnodeswasdefinedasnegative
or positive.
Immunohistochemical studies
The section with the deepest invasion was selected
and marked for the immunohistochemical ana-
lysis. The representative blocks were sectioned
and mounted on poly-L-lysin-coated slides. The
streptavidin-biotin-peroxidase method was per-
formed using primary monoclonal antibodies
against CD34 (c1one QBEnd/10, 1/200, Neomar-
kers, USA), TSP Ab-4 (clone A6.1, prediluted,
Neomarkers, USA), oestrogen receptor (ER) (pre-
diluted, Neomarkers, USA), and progesterone
receptor (PR) (prediluted, Neomarkers, USA).
Positive controls consisted of known positive sam-
ples of breast carcinoma for TSP Ab-4, ER, and
PR. Normal identifiable vessels within the sections
provided an internal control for CD34.
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Cytoplasmic staining in tumour cells and extracel-
lular fibrillary staining in the stroma juxtaposed to
tumour cells were defined positive. Semiquantitative
analysis of the immunostaining was performed
for each case. An estimate of the percentage of
immunoreactive cells was determined using a score
of 0 4 (0: negative; 1: 1% 25% cells stained; 2:
26% 50% cells stained; 3: 50% 75% cells stained;
4: 75% cells stained). The presence in the inva-
sion front of a distinct TSP-positive cell zone
composed of macrophages was scored into two
categories: 1) No TSP-positive stromal macro-
phages or B10% TSP-positive cell zone composed
of macrophages, 2) ]10% TSP-positive cell zone
composed of macrophages.
Assessment of vascularity
One representative block including the invasive
component of each breast tumour was selected and
marked for the immunohistochemical analysis. Mi-
crovessel counts were determined by using the
method of Weidner et al. (16). Microvessel density
(MVD) was determined by light microscopy in areas
of invasive tumour containing the highest numbers of
capillaries and small venules per area at low power
(40  and 100 ). The area of highest neovascular-
ization was identified. Microvessel counts were then
made on a 200 field (0.15 mm
2). Any endothelial
cell or cell cluster positive for CD34 and clearly
separate from an adjacent cluster was considered to
be a single, countable microvessel (16). Large vessels
with thick muscular walls and large vessel lumina
greater than approximately eight red blood cells were
excluded from the count (17). The maximum num-
ber of microvessels staining positive at 200  was
graded as: 1 ( B20 vessels), 2 (20 29 vessels), and
3 (]30 vessels).
Assessment of steroid hormone receptors
We followed Battifora and colleagues’ approach for
the determination of oestrogen receptor (ER) and
progesterone receptor (PR) expression and consid-
ered as positive all cases displaying easily discern-
ible nuclear staining in more than 5% of the
tumour cells (18).
Statistical analysis
Statistical analysis of the data was performed using
Mann-Whitney U test. The correlations between
the various parameters were determined by means
of the Pearson test. A P-value of 0.05 or less was
considered significant.
Results
Platelet counts, platelet TxB2, and cGMP levels
There was no statistically significant difference
between ages of control group and patient group.
Although platelet counts were within normal ranges
in both groups, the mean platelet count of the
patient group was significantly greater than the
mean platelet count of the control group (PB0.05)
(Table I). The platelet counts were positively corre-
lated with tumour size (r 0.609; PB0.01) (Figure
1). Platelet counts were higher in the patients who
had MVD grade 3 as compared with the patients
who had MVD grade 1 and MVD grade 2 (PB0.05)
(Figure 2). The mean basal platelet cGMP level in
the patient group was significantly lower than it was
in the control group (PB0.05). There was no
significant difference between TxB2 levels of the
controls and the patients.
Histopathological and immunohistochemical findings
The cellular distribution of TSP in tumour cells and
macrophages was cytoplasmic with a granular
texture. Fibrillary staining was observed in the
stroma juxtaposed to tumour cells. TSP immunor-
eactivity 525% was detectable in 5 (20%) of the
cases in the tumour cells, and in 9 (45%) of the cases
in the stroma (Figure 3; Table II). There was
a positive correlation between tumour cell TSP
staining and stromal TSP staining (PB0.01).
A TSP-positive cell zone composed of macrophages
adjacent to tumour cells was observed in 7 (35%) of
the tumours (Figure 4). No ductal or stromal
staining was observed in adjacent normal breast
tissue. Microvessels were noted to be most numer-
ous at the periphery of the infiltrating tumour cells
(Figure 5).
The Pearson test did not show the existence of
any significant correlations between the tumour cell
TSP staining, stromal TSP staining, TSP-positive
cell zone composed of macrophages, MVD, and any
of the conventional tumour features, including
Table I. Results of the blood and tissue analysis of the groups.
Control Patient
Platelet count (1000/mm
3) 236.79912.84 281.35917.12
a
Platelet TxB2 (ng /mL) 76.43910.37 84.5096.63
Platelet cGMP (pmol /mL) 1.4290.20 0.8590.11
a
Data presented as the mean9standard error of mean.
aPB0.05 as compared with that of control group.
110 C. Tokyol et al.tumour size, tumour grade, vascular invasion, status
of axillary lymph nodes, extranodal spread, ER
immunostatus, and PR immunostatus. There was
no correlation between TSP staining and MVD.
Discussion
Angiogenesis is the formation of new blood vessels
from the endothelium of the existing vasculature and
is essential for tumour growth and metastasis (19). It
has been previously shown that the density of
microvessels in an invasive breast carcinoma corre-
lates with the presence of metastasis (16). There are
reports that observed angiogenesis as an indepen-
dent and significant prognostic marker for survival in
early-stage breast carcinoma; several reports, how-
ever, have not been able to confirm the value of
angiogenesis as a prognostic marker (4).
Ultrastructural studies of experimental metastasis
showed that circulating tumour cells are frequently
surrounded by platelets (20). Platelets may promote
metastasis by releasing certain tumour growth factors
and by shielding tumour cells from immune surveil-
lance (11). It has been shown that thrombocytosis is
associated with a poor prognosis in lung and
endometrial carcinoma (21 23). The platelet counts
were within normal ranges in the patient group, but
they were significantly greater than the control
group. The higher platelet counts in breast carci-
noma patients and the positive correlation between
platelet count and tumour diameter confirm the
essential role of platelets in tumourigenesis.
Recently the hypothesis that platelets are an
important factor in angiogenesis has been proposed
(24,25). Platelets may affect angiogenesis by release
of angiogenesis-related factors. The hypothesis is
based on clinical and preclinical findings that
tumour angiogenesis is dependent not only on
endothelial cells and tumour cells, but also on
platelet-endothelium interaction (25). We observed
that platelet counts were higher in the patients who
had MVD grade 3. This finding confirms the effect
of platelets on angiogenesis.
TxA2 is the major vasoconstrictor and stimulator
of platelet aggregation. There are inconclusive
results about the role of TxA2 in tumour-induced
platelet aggregation (TIPA) (26). Thrombin-in-
duced TxA2 generation of the platelets was deter-
mined by measuring levels of TxB2, a stable
metabolite of TxA2. We did not find any difference
in TxB2 levels of the patients and the controls.
Intraplatelet cGMP acts to inhibit aggregation
(27). It is associated with endothelial function (28).
CGMP is synthesized in platelets through a soluble
guanylate cyclase, activated by nitrovasodilators and
NO (29). NO levels were determined in several
malignant tissues (30 32). Tumour cell-associated
high levels of NO were reported (30,33). Di Nicola
et al. also found high levels of cGMP in malignant
tissue (30). We did not evaluate NO or cGMP
levels in malignant tissue, but we found lower levels
of cGMP in patients. Decreased levels of cGMP
may cause platelet hyperreactivity. Jurasz et al.
mentioned that how the platelet-inhibitory effects
of NO translate into regulation of cancer growth,
invasion, and metastasis was uncertain. They
Figure 2. Platelet counts in the patients who had microvessel
density (MVD) grade 1, grade 2, and grade 3.
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Figure 1. Correlation between platelet counts and tumour size.
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complexity of NO effects (26). It seems that further
studies are needed to explain the role of the NO-
cGMP pathway in carcinogenesis and TIPA.
TSP is a matricellular protein that does not
function as structural component of extracellular
matrix but interacts with matrix proteins, cell surface
receptors, or other molecules that interact with the
cell surface (34). Five subtypes of TSPs have been
identified (35). TSP-1 was first described as a
product of platelets (36). In addition to platelets, a
variety of other cells have been found to contain and
secrete TSP-1, including endothelial cells, smooth
muscle cells, fibroblasts, pneumocytes, macro-
phages, monocytes, and tumour cells (37 39).
TSP-1 modulates cell-cell interaction and promotes
the adhesion and aggregation of platelets (40 42).
It functions as an angiogenesis inhibitor (5). Using
immunohistochemical techniques, Wong et al. found
in 37 specimens of invasive ductal carcinoma that
TSP stained strongly in the desmoplastic stroma or
at the basement membrane associated with the
malignant ductal epithelium. Stronger TSP staining
was seen in the poorly differentiated tumours. In six
cases of ductal carcinoma in situ TSP staining was
confined to the basement membrane of the involved
ducts. TSP could not be demonstrated in the base-
ment membrane of normal breast epithelium (43).
Clezardin et al. observed a weak staining in
the basement membrane of normal ductules and a
strong immunostaining for TSP-1 in the basement
membrane surrounding in situ carcinomas. In 20
cases of invasive ductal carcinomas studied, a weak
staining for TSP-1 was observed in 10% of invasive
Figure 3. A: Cytoplasmic thrombospondin (TSP) staining with a granular texture in tumour cells and ﬁbrillary staining in the stroma
juxtaposed to tumour cells ( 200). B: Fibrillary TSP staining in the tumour stroma ( 40).
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desmoplasia of invasive ductal carcinomas. This
finding was consistent with the fact that fibroblasts
synthesize and secrete TSP-1 and that TSP-1
promotes both adhesion and growth of fibroblasts
(44).
Wang-Rodriguez et al. reported that TSP-1
expression was significantly higher in malignant
Table II. Histopathological and immunohistochemical ﬁndings of the 20 cases of breast carcinoma.
MVD
Tumour Cell
TSP staining
Stromal TSP
staining
TSP-positive
stromal
macrophages
Parameters stu-
died
Mean age
(y)
Patients
(n)1   2  3  01 0 1 B10% ]10%
Tumour size
52 cm 60 12 (60%) 6 (30%) 4 (20%) 2 (10%) 9 (45%) 3 (15%) 5 (25%) 7 (35%) 8 (40%) 4 (20%)
 2 cm 51 8 (40%) 4 (20%) 2 (10%) 2 (10%) 6 (30%) 2 (10%) 6 (30%) 2 (10%) 5 (25%) 3 (15%)
Histological grade
a
1 55 14 (70%) 7 (35%) 5 (25%) 2 (10%) 11 (55%) 3 (15%) 9 (45%) 5 (25%) 9 (45%) 5 (25%)
2 60 6 (30%) 3 (15%) 1 (5%) 2 (10%) 4 (20%) 2 (10%) 2 (10%) 4 (20%) 4 (20%) 2 (10%)
In situ component
Negative 61 11 (55%) 7 (35%) 3 (15%) 1 (5%) 8 (40%) 3 (15%) 5 (25%) 6 (30%) 7 (35%) 4 (20%)
Positive 51 9 (45%) 3 (15%) 3 (15%) 3 (15%) 7 (35%) 2 (10%) 6 (30%) 3 (15%) 6 (30%) 3 (15%)
Vascular invasion
Negative 57 16 (80%) 8 (40%) 4 (20%) 4 (20%) 12 (60%) 4 (20%) 8 (40%) 8 (40%) 11 (55) 5 (25%)
Positive 54 4 (20%) 2 (10%) 2 (10%) 3 (15%) 1 (5%) 3 (15%) 1 v(5%) 2 (10%) 2 (10%)
Status of axillary lymph nodes
Negative 59 8 (40%) 2 (10%) 4 (20%) 2 (10%) 6 (30%) 2 (10%) 4 (20%) 4 (20%) 5 (25%) 3 (15%)
Positive 55 12 (60%) 8 (40%) 2 (10%) 2 (10%) 9 (45%) 3 (15%) 7 (35%) 5 (25%) 8 (40%) 4 (20%)
Extranodal spread
Negative 55 7 (35%) 5 (25%) 1 (5%) 1 (5%) 5 (25%) 2 (10%) 4 (20%) 3 (15%) 4 (20%) 3 (15%)
Positive 47 5 (25%) 3 (15%) 1 (5%) 1 (5%) 4 (20%) 1 (5%) 3 (15%) 2 (10%) 4 (20%) 1 (5%)
Status of ER
Negative 58 9 (45%) 5 (25%) 1 (5%) 3 (15%) 7 (35%) 2 (10%) 5 (25%) 4 (20%) 7 (35%) 2 (10%)
Positive 55 11 (55%) 5 (25%) 5 (25%) 1 (5%) 8 (40%) 3 (15%) 6 (30%) 5 (25%) 6 (30%) 5 (25%)
Status of PR
Negative 58 11 (55%) 4 (20%) 3 (15%) 4 (20%) 8 (40%) 3 (15%) 6 (30%) 5 (25%) 8 (40%) 3 (15%)
Positive 55 9 (45%) 6 (30%) 3 (15%) 7 (35%) 2 (10%) 5 (25%) 4 (20%) 5 (25%) 4 (20%)
a There are no grade 3 cases.
Figure 4. Thrombospondin (TSP)-positive macrophages adjacent to tumour cells ( 400).
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sources, but no difference in expression levels was
evident between primary tumours with or without
metastases, nor between primary and metastatic
carcinomas. They observed very weak staining in
normal tissues, and no TSP-1 was detected in breast
tissue stromal components (45).
In the present study, only focal TSP immunor-
eactivity 520% was detectable in 5 (20%) of the
tumours in the tumour cells, and in 9 (45%) of the
tumours in the stroma. There was a positive
correlation between tumour cell TSP staining and
stromal TSP staining. Intensity of staining ranged
from weak to moderate. The tumours included in
our study were grade 1 and grade 2. This may be
the reason for weak to moderate staining of the
tumours. Stronger staining may be observed if grade
3 tumours were included. A TSP-positive cell zone
composed of macrophages was observed in 7 (%35)
of the tumours. Tumour-infiltrating macrophages
may be a major source of TSP-1 as well as tumour
cells and tumour-associated stroma. We did not find
any correlation between TSP-1 staining and angio-
genesis, platelet counts, platelet activity, and the
histological prognostic parameters we have studied.
No ductal or stromal TSP staining was observed in
adjacent normal breast tissue.
The present study evaluated angiogenesis and
expression of TSP-1 in invasive ductal carcinoma of
the breast and their relation with platelet activity.
The platelet counts were positively correlated with
tumour size and were higher in the patients who had
MVD grade 3. This confirms the essential role of
platelets in tumour growth and angiogenesis. We
found increased platelet counts and decreased
cGMP levels in the patient group. Since cGMP level
is accepted as an index of NO production, we
thought that further studies are needed to explain
the role NO-cGMP pathway in carcinogenesis and
TIPA. Although TSP-1 may be upregulated in
malignant breast tissue, this is not sufficient for
tumour growth and dissemination according to our
results.
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